Janssen Biotech, Inc.

Xencor, Inc.

Genmab A+s

Adam Zwolak

Rajkumar Ganesan

Sanjaya Singh

Fang Yi

John R Desjarlais

Gregory L Moore

Jinquan Luo

Michael Hedvat

Mark Chiu

Juan Diaz

Colleen Kane

Sherry La Porte

Veronica Gusti Zeng

Raymond Brittingham

Matthew Adam Dragovich

Fei Shen

Fouad Moussa

Joseph Erhardt

Triveni K Bhatt

Scott R Brodeur

Theresa McDevitt

Pankaj Seth

Paul Parren

Janine Schuurman

Steven Jacobs

Aran Frank Labrijn

Joyce Meesters

Thomas C Nesspor

Sylvie Laquerre

Anthony A Armstrong

Michael Dennis Feldkamp

Dirk Brehmer

Martin Jack Borrok, Iii

Jaclyn Hoover

Ninkka Tamot

Paul B Harvilla

Szeman Chan

Ian White

Desiree De Lange

Rajitha Doddareddy

Natasa Obermajer

Matthew Bunce

Julien Häsler

Shana Versmissen

Kelly Van De Ven

Theodore D Petley

Joyce I Meesters

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising CD3 antigen binding domains and uses thereof

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

Materials and methods for multidirectional biotransportation in virotherapeutics

Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.

Materials and methods of using engineered ligands

The invention provides antigen binding domains that bind human leukocyte antigen G (HLA-G) protein comprising the antigen binding domains that bind HLA-G, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising HLA-G antigen binding domains and their uses

The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations

Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

Rodent bispecific heterodimeric proteins

Growing community of inventors

Bala Cynwyd, PA, United States of America

Adam Zwolak